Author: kodiac

  • Salidroside

    Phenylpropanoid glycoside (tyrosol 8-O-beta-D-glucopyranoside) adaptogen with pleiotropic antioxidant, anti-inflammatory, and neuroprotective activity

    A naturally occurring phenylethanol glycoside isolated from Rhodiola rosea and related Crassulaceae species, characterized by activation of the AMPK/Nrf2 axis and inhibition of NF-kappaB-driven inflammation, with a broad preclinical evidence base spanning neuroprotection, cardioprotection, metabolic regulation, and anti-tumor activity, and emerging clinical evidence in stress adaptation and exercise performance.

    Abstract

    Salidroside (2-(4-hydroxyphenyl)ethyl beta-D-glucopyranoside; CAS 10338-51-9) is the principal bioactive glycoside of the adaptogenic plant Rhodiola rosea L. and related Rhodiola species of the family Crassulaceae. It is the 8-O-beta-D-glucoside of tyrosol (4-hydroxyphenylethanol), a simple phenylethanol aglycone that is also the primary circulating metabolite of salidroside following oral administration. The compound has been used in traditional Tibetan, Chinese, and Scandinavian medicine for centuries as a general tonic and adaptogen, and modern pharmacological investigation has identified a remarkably diverse spectrum of biological activities centered on three principal molecular mechanisms: activation of the AMP-activated protein kinase (AMPK) signaling cascade with downstream engagement of the PI3K/Akt/GSK3beta and SIRT1 pathways; activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant response axis; and suppression of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) pro-inflammatory transcriptional program with consequent reduction of tumor necrosis factor alpha, interleukin-1 beta, interleukin-6, and NLRP3 inflammasome activation.

    Preclinical pharmacology studies conducted across multiple organ systems have demonstrated neuroprotective efficacy in models of cerebral ischemia/reperfusion injury, Alzheimer’s disease (amyloid beta-induced neurotoxicity and ferroptosis), Parkinson’s disease (MPTP and 6-OHDA models), traumatic brain injury, and depression; cardioprotective activity against ischemia/reperfusion injury, doxorubicin-induced cardiotoxicity, and atherosclerosis; hepatoprotective effects against carbon tetrachloride and high-fat-diet-induced liver injury and nonalcoholic steatohepatitis; antidiabetic activity through amelioration of insulin resistance via the mitochondria-associated AMPK/PI3K/Akt/GSK3beta pathway; renoprotective effects in diabetic nephropathy; and anti-tumor activity in breast, lung, colorectal, and gastric cancer models through inhibition of proliferation, migration, and invasion via the AKT and MEK/ERK signaling pathways.

    Pharmacokinetics in rodents are characterized by rapid oral absorption (Tmax approximately 0.5 to 1 hour), moderate oral bioavailability (approximately 20 to 32 percent in rats), extensive first-pass metabolism to the aglycone p-tyrosol by intestinal and hepatic beta-glucosidases, wide tissue distribution with preferential accumulation in kidney, liver, and heart, and renal elimination of conjugated metabolites. The compound crosses the blood-brain barrier. Salidroside demonstrates a favorable safety profile: the acute oral LD50 in rats exceeds 5000 mg/kg body weight, and subchronic toxicity studies at doses up to 100 mg/kg/day have not produced organ toxicity, genotoxicity, or teratogenicity at the studied doses.

    Human clinical evidence remains limited relative to the preclinical literature. Rhodiola rosea standardized extracts containing salidroside (typically standardized to 1 to 3 percent salidroside) have demonstrated efficacy in randomized controlled trials for stress-related fatigue, mild to moderate depression, generalized anxiety, and cognitive function under stress conditions. A 2024 exploratory randomized double-blind placebo-controlled trial of pure biosynthetic salidroside at 60 mg/day for 16 days in healthy active young adults demonstrated enhanced oxygen utilization during high-intensity intermittent exercise, stable mood states, and mitigated exercise-induced muscle damage. A randomized controlled trial of 60 breast cancer patients reported no clinical adverse events during salidroside administration as adjunctive therapy.

    This monograph reviews the chemistry, natural and synthetic sources, and structural pharmacology of salidroside; the multi-target molecular mechanisms across the AMPK, Nrf2, and NF-kappaB axes; the comprehensive preclinical pharmacology across neurological, cardiovascular, metabolic, hepatic, renal, and oncological models; the available human pharmacokinetic and clinical evidence; sourcing, quality verification, and standardization considerations; reconstitution and handling protocols; stack-interaction implications; adverse-event and safety signal characterization; and a structured comparative assessment of five adaptogenic or neuroprotective compounds against salidroside on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1613Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Itruvone

    Synthetic pregnane neuroactive steroid vomeropherine acting via nasal chemosensory receptor activation of olfactory-amygdala neural circuits

    A synthetic pregnane steroid pherine developed by Pherin Pharmaceuticals and advanced by VistaGen Therapeutics as an intranasal microgram-dose nasal spray for major depressive disorder, distinguished from all approved antidepressants by a proposed non-systemic mechanism of action operating through peripheral nasal chemosensory neuron activation of limbic-hypothalamic catecholaminergic circuits without requirement for blood-brain barrier penetration or direct central nervous system receptor engagement.

    Abstract

    Itruvone (PH10; pregn-4-en-20-yn-3-one; CAS 21321-89-1) is a synthetic neuroactive steroid of the pregnane class and the second clinical-stage pherine (vomeropherine) molecule, under development by VistaGen Therapeutics as an intranasal nasal spray for the treatment of major depressive disorder (MDD). The compound is structurally characterized by a 17-alpha-ethynyl substituent on the pregnane steroid nucleus and a 3-keto-4-ene A-ring motif, yielding an odorless crystalline material with a molecular weight of 296.45 g/mol and the molecular formula C21H28O. Itruvone is pharmacologically distinguished from all currently approved antidepressants, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and the rapid-onset agents esketamine and brexanolone, by a proposed mechanism of action that does not require systemic absorption or direct activity on neuronal receptors in the brain. Instead, the compound is administered at microgram-level intranasal doses (3.2 to 6.4 micrograms per day) and is designed to engage and activate chemosensory receptor neurons in the nasal epithelium, which in turn activate olfactory bulb projections to the amygdala, hypothalamus, and prefrontal cortex through olfactory-amygdala neural circuits believed to modulate the activity of the limbic-hypothalamic sympathetic nervous system and increase the release of catecholamines from midbrain nuclei.

    Preclinical tissue distribution studies using radiolabeled [14C]PH10 in rats demonstrated that a single intranasal administration was essentially undetectable in the brain and most other tissues, including blood and plasma, supporting the hypothesis that therapeutic activity occurs through peripheral chemosensory signaling rather than through systemic drug exposure. Preclinical electrophysiology studies further demonstrated that itruvone’s mechanism does not involve direct activation of GABA-A receptors in the brain, differentiating it from benzodiazepines and from the neurosteroid antidepressant brexanolone (allopregnanolone).

    The clinical evidence base comprises a positive Phase 2A randomized, double-blind, placebo-controlled trial conducted in Mexico in 30 patients with MDD, in which daily self-administered intranasal itruvone at 6.4 micrograms produced a mean 17-item Hamilton Depression Rating Scale (HAM-D-17) score reduction of 10.1 points after one week (compared to 4.2 points for placebo, p = 0.03) and 17.8 points after eight weeks, with the drug well tolerated and minimal side effects reported; a successful U.S. Phase 1 safety and tolerability study in healthy adult subjects completed in 2023 with no serious adverse events, no discontinuations due to adverse events, and only two mild adverse events (fatigue and headache in the same subject); and supportive prior clinical studies. The U.S. Food and Drug Administration has granted Fast Track designation for the development of itruvone as a potential treatment for MDD.

    This monograph reviews the chemistry, structural classification, and synthesis of itruvone; the pherine pharmacology and nasal chemosensory receptor mechanism; the available pharmacokinetic and tissue distribution data; preclinical pharmacology including electrophysiology and tissue distribution studies; the clinical evidence base across Phase 1 and Phase 2A trials; sourcing and quality verification for research-grade material; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five alternative antidepressant approaches against itruvone on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority for any indication. It is an investigational drug in clinical development; investigators should obtain appropriate regulatory authorization before any human research application.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1587Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Bryostatin-1

    Macrocyclic lactone protein kinase C modulator with sub-nanomolar affinity for the C1 regulatory domain

    A marine-derived macrolide isolated from the bryozoan Bugula neritina, distinguished from classical phorbol ester PKC activators by isoform-selective modulation producing anti-inflammatory, synaptogenic, and latent HIV-reversing activity at sub-nanomolar concentrations without tumor-promoting effects.

    Abstract

    Bryostatin-1, the prototypical member of the bryostatin family of macrocyclic lactones, is a highly oxygenated 26-membered macrolide originally isolated from the marine bryozoan Bugula neritina and subsequently attributed to the bacterial endosymbiont Candidatus Endobugula sertula. The compound binds the C1 regulatory domain of protein kinase C (PKC) at the conserved diacylglycerol (DAG) binding site with sub-nanomolar affinity, modulating both conventional (alpha, betaI/betaII, gamma) and novel (delta, epsilon, eta, theta) PKC isoforms. Despite competitive displacement of phorbol esters from the C1 domain, bryostatin-1 produces functionally distinct downstream signaling characterized by initial PKC activation followed by isoform-selective downregulation, a pharmacological profile that distinguishes it from tumor-promoting phorbol esters and underwrites its diverse therapeutic applications across oncology, neurology, immunology, and infectious disease.

    The compound entered clinical development through the National Cancer Institute (NCI) in the early 1990s as an antineoplastic agent, advancing through more than 80 Phase 1 and Phase 2 oncology trials enrolling over 1,500 patients across multiple solid tumor and hematological malignancy indications. The principal dose-limiting toxicity in oncology trials was myalgia, observed at doses of 25 to 50 micrograms per square meter administered by intravenous infusion. Single-agent antitumor activity was modest, though combination regimens with cytarabine in acute myeloid leukemia and with vincristine in non-Hodgkin lymphoma produced response rates warranting further investigation. The oncology program did not yield a registration-quality efficacy signal, and active NCI-sponsored oncology development was substantially curtailed by 2010.

    A second clinical trajectory, initiated by Alkon and colleagues at the Blanchette Rockefeller Neurosciences Institute and subsequently advanced by Synaptogenix (formerly Neurotrope), repositioned bryostatin-1 as a cognitive enhancement agent for Alzheimer’s disease on the basis of PKC epsilon activation, synaptogenesis induction, and amyloid precursor protein alpha-secretase processing. A Phase 2a trial (Nelson et al. 2017) demonstrated safety at 25 micrograms per square meter and produced signals of PKC epsilon activation and cognitive stabilization. A larger NIH-sponsored Phase 2 trial (NCT04538066) in 122 patients with moderately severe Alzheimer’s disease reported that the primary endpoint (change from baseline in Severe Impairment Battery score at week 28) was not met with statistical significance across the full analysis population. However, prespecified secondary analysis of the severe cohort (Mini-Mental State Examination 10 to 14) demonstrated that bryostatin-treated patients showed no significant cognitive decline over 10 months, compared with placebo patients who declined by 12.8 Severe Impairment Battery points, a finding published in the Journal of Alzheimer’s Disease in 2023. The compound was well tolerated in the Alzheimer’s trials with no drug-related serious adverse events and no cases of the myalgia observed at higher oncology doses.

    A third research application addresses HIV latency reversal. Bryostatin-1 reactivates latent HIV-1 provirus through PKC-mediated NF-kappaB activation in both lymphocytic and monocytic cellular reservoirs, including astrocytes, at low nanomolar concentrations. The Wender laboratory at Stanford developed a scalable 29-step total synthesis (2017) and characterized synthetic bryostatin analogs (bryologs) as latency-reversing agents with an expanded therapeutic window, establishing the foundation for a “kick and kill” eradication strategy in combination with antiretroviral therapy.

    Pharmacokinetics following intravenous administration are characterized by a two-compartment disposition model with distribution and elimination half-lives of approximately 1 and 23 hours, respectively. The compound distributes widely to lung, liver, gastrointestinal tract, and adipose tissue, with evidence of enterohepatic circulation. Renal excretion accounts for approximately 23 percent of the administered dose in the first 12 hours; fecal excretion accounts for approximately 40 percent by 72 hours. The compound is not orally bioavailable at therapeutically relevant concentrations and is administered exclusively by intravenous infusion in clinical applications.

    This monograph reviews the chemistry, natural source, total synthesis, and supply chain of bryostatin-1; the PKC isoform pharmacology in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across oncology, Alzheimer’s disease, and HIV latency reversal indications; reconstitution, sourcing, and handling considerations for laboratory work; stack-interaction implications; the adverse-event and safety profile; and a comparative assessment of five PKC-modulating compounds (prostratin, ingenol mebutate, phorbol 12-myristate 13-acetate, SUW133, and TPPB) against bryostatin-1 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority for any indication. It is supplied as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1578Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Tretinoin

    Endogenous retinoid and pan-retinoic acid receptor agonist with genomic transcriptional regulation

    The principal biologically active metabolite of vitamin A, functioning as a pan-RAR agonist that regulates epithelial differentiation, collagen biosynthesis, and myeloid cell maturation, with established clinical applications spanning topical dermatology, photoaging reversal, and systemic differentiation therapy of acute promyelocytic leukemia.

    Abstract

    Tretinoin (all-trans-retinoic acid, ATRA) is the carboxylic acid form of vitamin A and the principal endogenous ligand of the nuclear retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma), through which it regulates the transcription of over 500 target genes involved in cellular differentiation, proliferation, apoptosis, and immune modulation. First isolated and characterized in the mid-twentieth century as a metabolite of retinol, tretinoin was developed as a topical dermatological agent by Albert Kligman and James Fulton at the University of Pennsylvania in the 1960s and received United States Food and Drug Administration approval for acne vulgaris in 1971, making it the first retinoid approved for clinical use. The compound was subsequently approved for the treatment of fine facial wrinkles and mottled hyperpigmentation associated with photoaging in 1995. In the systemic setting, the landmark 1988 report by Huang and colleagues at Shanghai Second Medical University demonstrated that oral tretinoin at 45 mg/m2/day induced complete hematological remission in patients with acute promyelocytic leukemia (APL) harboring the t(15;17) translocation and the resulting PML-RAR-alpha fusion oncoprotein, establishing tretinoin as the first successful differentiation therapy in oncology and transforming APL from a rapidly fatal malignancy to one of the most curable forms of acute leukemia. The molecular pharmacology of tretinoin is mediated through ligand-dependent activation of RAR/RXR heterodimers bound to retinoic acid response elements in target gene promoters; in the unliganded state, these heterodimers recruit corepressor complexes (NCoR, SMRT) and histone deacetylases that maintain transcriptional silencing, while tretinoin binding induces conformational change, corepressor release, and coactivator recruitment with histone acetyltransferase activity, resulting in chromatin remodeling and transcriptional activation. In the dermatological context, this transcriptional program promotes keratinocyte differentiation, accelerates corneocyte shedding, inhibits comedone formation, stimulates type I procollagen synthesis, and blocks ultraviolet-induced matrix metalloproteinase activation through inhibition of activator protein 1. In APL, pharmacological concentrations of tretinoin overcome the dominant-negative transcriptional repression imposed by the PML-RAR-alpha fusion protein, driving terminal granulocytic differentiation of the leukemic clone.

    Pharmacokinetics differ substantially between the topical and systemic routes. Topical application produces minimal systemic absorption, with percutaneous bioavailability estimated at less than 2 percent and negligible alteration of endogenous plasma retinoid concentrations. Oral tretinoin at the 45 mg/m2 APL dose is rapidly absorbed, reaching peak plasma concentrations of approximately 350 ng/mL (1.2 micromolar) within 1 to 2 hours, with greater than 95 percent plasma protein binding predominantly to albumin. The terminal elimination half-life is short (0.5 to 2 hours) and is dominated by oxidative metabolism through CYP26A1, CYP2C8, and CYP3A4, with a clinically significant autoinduction phenomenon: tretinoin potently upregulates CYP26A1 transcription through retinoic acid response elements in the CYP26A1 promoter, resulting in progressive acceleration of its own clearance such that plasma concentrations decline to approximately one-third of initial values within one week of continuous dosing at constant dose. This autoinduction has clinical implications for APL treatment duration and has motivated intermittent dosing schedules and combination regimens with arsenic trioxide. The compound is teratogenic through disruption of retinoic acid gradient signaling during embryogenesis, classified as FDA pregnancy category X for systemic use; topical tretinoin, by contrast, does not produce measurable increases in systemic retinoid exposure and is not associated with increased teratogenic risk in epidemiological studies, though precautionary avoidance during pregnancy is recommended. The principal systemic toxicity in APL therapy is the differentiation syndrome (formerly retinoic acid syndrome), a potentially fatal inflammatory response occurring in approximately 25 percent of treated patients and characterized by fever, dyspnea, weight gain, pulmonary infiltrates, and pleural or pericardial effusions, managed with early recognition and high-dose corticosteroids.

    This monograph reviews the chemistry, structural identity, and synthesis of tretinoin; the RAR/RXR nuclear receptor pharmacology and downstream transcriptional programs; the divergent pharmacokinetics of topical and systemic administration including autoinduction; the preclinical pharmacology across dermatological, oncological, and wound-healing models; the clinical evidence base in acne, photoaging, and acute promyelocytic leukemia; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a comparative assessment of five retinoid alternatives (adapalene, tazarotene, isotretinoin, bexarotene, tamibarotene) against tretinoin on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1566Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • DNL343

    Small molecule eukaryotic initiation factor 2B (eIF2B) activator and integrated stress response (ISR) inhibitor

    A potent, selective, CNS-penetrant bicyclo[1.1.1]pentane-centered eIF2B activator developed by Denali Therapeutics for the suppression of aberrant integrated stress response signaling in neurodegenerative disease, advanced through Phase 2/3 clinical evaluation in amyotrophic lateral sclerosis.

    Abstract

    DNL343 is a first-in-class, orally bioavailable, brain-penetrant small molecule activator of eukaryotic initiation factor 2B (eIF2B), the guanine nucleotide exchange factor that governs the rate-limiting step in translation initiation and serves as the principal regulatory node of the integrated stress response (ISR). The compound was designed at Denali Therapeutics as an improvement over the prototype tool compound ISRIB, which despite landmark demonstrations of cognitive enhancement and neuroprotection in rodent models suffered from poor aqueous solubility, limited oral bioavailability, and pharmaceutical intractability [1, 2]. DNL343 retains the symmetric bis-glycolamide pharmacophore that stabilizes the eIF2B decameric complex at the subunit interface but replaces the central cyclohexane of ISRIB with a bicyclo[1.1.1]pentane (BCP) bioisostere, conferring improved solubility, metabolic stability, and CNS penetration [3]. The compound displays an IC50 of 3.2 nanomolar in a cellular ATF4 reporter assay, a brain-to-plasma unbound concentration ratio of approximately 0.8 in rat, and a plasma elimination half-life of 31 to 46 hours in healthy human subjects, supporting once-daily oral dosing [3, 4, 5].

    Preclinically, DNL343 produced dose-dependent neuroprotection in an optic nerve crush model of acute retinal ganglion cell degeneration and, in the Eif2b5 R191H knock-in mouse model of vanishing white matter disease (a genetic ISR-driven leukoencephalopathy), restored body weight, normalized motor function, reversed ISR transcriptional signatures, normalized plasma neurofilament light chain (NfL), and extended survival from 25 percent to 84.6 percent of treated animals when administered therapeutically at advanced disease stages [1]. In inducible TDP-43 proteinopathy mouse models relevant to amyotrophic lateral sclerosis (ALS), DNL343 attenuated ISR activation and reduced markers of neurodegeneration [6].

    Clinical development proceeded through a Phase 1 trial in 95 healthy volunteers (single ascending doses of 15 to 800 mg; multiple ascending doses of 45 to 260 mg daily for 14 days), which demonstrated dose-proportional pharmacokinetics, cerebrospinal fluid (CSF) to unbound plasma ratios of 0.66 to 0.92, robust suppression of ISR biomarkers (ATF4 protein, CHAC1 transcript) in peripheral blood mononuclear cells, and a favorable tolerability profile with no serious adverse events [4, 5]. A Phase 1b study in 28 participants with ALS (100 and 200 mg daily for 28 days, followed by an 18-month open-label extension) confirmed CNS penetration with CSF-to-unbound-plasma ratios of 1.02 to 1.23, pharmacodynamic target engagement, and acceptable safety, with headache and fatigue as the most common treatment-emergent adverse events [7, 8]. The compound was subsequently advanced to Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, a 24-week randomized, placebo-controlled study enrolling 186 participants on DNL343 and 139 on placebo. In January 2025, Denali Therapeutics announced that the trial did not meet its primary endpoint of slowing disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) and survival, and key secondary endpoints including muscle strength and respiratory function showed no statistical separation from placebo [9, 10]. A subsequent SEC filing revealed that DNL343 did not alter NfL biomarker levels over the treatment period [10]. The compound is no longer in active clinical development for ALS.

    This monograph reviews the chemistry and design rationale of DNL343; the molecular pharmacology of eIF2B activation and ISR suppression; the comprehensive preclinical neuroprotection evidence; human pharmacokinetics across Phase 1 and Phase 1b studies; the clinical evidence base in ALS; sourcing, reconstitution, and handling considerations for research applications; stack interactions; the adverse-event profile; and a structured comparative assessment of five ISR-modulating agents (ISRIB, 2BAct, fosigotifator/ABBV-CLS-7262, IFB-088/Sephin1, and trazodone) against DNL343 on five competency standards. The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers; investigators should confirm identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1574Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Lisuride

    Semisynthetic 8-alpha-ergoline dopamine D2/D3 receptor agonist with multimodal serotonergic, adrenergic, and histaminergic activity

    A semisynthetic ergot alkaloid dopamine agonist distinguished from other ergolines by 5-HT2B receptor antagonism (conferring absence of cardiac valvulopathy risk), G protein-biased 5-HT2A partial agonism without hallucinogenic activity, and broad translational applications spanning Parkinson’s disease, hyperprolactinemia, migraine prophylaxis, and emerging antidepressant research.

    Abstract

    Lisuride (1,1-diethyl-3-[(8-alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea) is a semisynthetic 8-alpha-ergoline derivative first synthesized by Zikan and Semonsky at the Research Institute for Pharmacy and Biochemistry in Prague in 1960 as an antimigraine agent analogous to methysergide. It was subsequently developed by Schering AG (Berlin) as a dopamine D2/D3 receptor agonist for the treatment of Parkinson’s disease, hyperprolactinemia, and migraine prophylaxis, and has been marketed in multiple European, Asian, and Latin American jurisdictions under the brand names Dopergin, Cuvalit, Lysenyl, Revanil, and others. Lisuride is the most potent of the classical ergoline dopamine agonists by receptor binding affinity, with sub-nanomolar Ki values at the dopamine D2 and D3 receptors and the serotonin 5-HT1A receptor, and low-nanomolar affinity across a broad panel of monoamine targets including dopamine D1, D4, and D5 receptors, serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, alpha-1 and alpha-2 adrenergic receptors, and the histamine H1 receptor. This broad receptor engagement, sometimes characterized as “dirty drug” pharmacology, produces a clinically diverse profile that distinguishes lisuride from both the older ergoline bromocriptine and the newer non-ergoline dopamine agonists ropinirole and pramipexole.

    Two pharmacological features of lisuride have attracted particular research interest in the 2020s. First, lisuride is a silent antagonist at the serotonin 5-HT2B receptor, in contrast to the ergoline dopamine agonists pergolide and cabergoline, which are 5-HT2B agonists. Because 5-HT2B receptor agonism on cardiac valvular interstitial cells is the established molecular mechanism of the fibrotic cardiac valvulopathy that led to the withdrawal of pergolide and the black-box labeling of cabergoline, the 5-HT2B antagonist profile of lisuride is associated with the absence of cardiac valvulopathy adverse drug reaction reports in pharmacovigilance databases, supporting the concept that 5-HT2B agonism (not ergoline structure per se) is the critical determinant of fibrotic risk [1]. Second, lisuride is a G protein-biased partial agonist at the serotonin 5-HT2A receptor: it activates 5-HT2A-mediated Gq/11 signaling without recruiting beta-arrestin 2, and in consequence does not produce the head-twitch response in rodents or hallucinogenic activity in humans that characterizes the structurally related lysergic acid diethylamide (LSD) and other beta-arrestin-biased 5-HT2A agonists [2, 3]. This biased signaling profile has positioned lisuride as a key pharmacological tool for dissecting the signaling pathways responsible for psychedelic versus therapeutic 5-HT2A receptor effects, and recent preclinical evidence demonstrates that lisuride exerts antidepressant-like and psychoplastogenic effects in mice through G protein-dependent mechanisms without hallucinogenic activity [3].

    Pharmacokinetics of oral lisuride are characterized by complete gastrointestinal absorption, high first-pass hepatic metabolism reducing absolute oral bioavailability to 10 to 20 percent, peak plasma concentrations at 60 to 80 minutes, a short elimination half-life of approximately 2 hours, and plasma protein binding of 60 to 70 percent [4]. More than 15 metabolites have been identified. The short half-life motivated the development of continuous subcutaneous infusion protocols for advanced Parkinson’s disease with motor fluctuations (lisuride was the first dopamine agonist used for chronic subcutaneous pump delivery) and transdermal patch formulations intended to provide sustained plasma concentrations and continuous dopaminergic stimulation [5, 6]. Clinical evidence in Parkinson’s disease demonstrates that continuous subcutaneous lisuride infusion significantly reduces off-time and dyskinesia compared to oral levodopa, with sustained benefit over four years in prospective randomized trials [7]. Oral lisuride at doses of 0.6 to 5 mg daily has demonstrated comparable antiparkinsonian efficacy to bromocriptine in adjunctive therapy, though firm conclusions on oral efficacy are limited by the absence of large randomized controlled trials [8, 9]. The compound is well tolerated at clinical doses; the principal adverse events are nausea, dizziness, orthostatic hypotension, and psychiatric effects (hallucinations, confusion) at higher doses, consistent with the dopamine agonist class. The absence of cardiac valvulopathy signal distinguishes the safety profile from pergolide and cabergoline. This monograph reviews the chemistry, synthesis, and receptor pharmacology of lisuride; the comprehensive pharmacokinetic record across oral, subcutaneous, and transdermal routes; the clinical evidence base across Parkinson’s disease, hyperprolactinemia, migraine, and emerging antidepressant indications; sourcing, reconstitution, and stack-interaction considerations; adverse-event signal and safety; and a comparative assessment of five dopamine agonist alternatives against lisuride on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1590Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Bacoside A

    Dammarane-type triterpenoid saponin mixture with multi-target nootropic, antioxidant, and neuroprotective activity

    A mixture of dammarane-type triterpenoid saponin glycosides isolated from Bacopa monnieri (Linn.) Wettst., constituting the principal bioactive fraction responsible for the cognitive-enhancing, neuroprotective, and antioxidant pharmacology of the Ayurvedic nootropic brahmi, with demonstrated activity across cholinergic modulation, serotonergic and dopaminergic neurotransmission, amyloid-beta aggregation inhibition, and synaptic plasticity.

    Abstract

    Bacoside A is a mixture of four dammarane-type triterpenoid saponin glycosides (bacoside A3, bacopaside II, bacopasaponin C, and bacopaside X) isolated from the aerial parts and roots of Bacopa monnieri (Linn.) Wettst. (family Plantaginaceae, formerly Scrophulariaceae), a creeping perennial herb used in the Ayurvedic medical tradition for over three millennia under the name brahmi as a medhya rasayana (intellect-rejuvenating) agent. The bacoside A fraction, typically comprising 40 to 55 percent of standardized Bacopa monnieri extracts by weight, is the principal pharmacologically active constituent and the basis of standardization for all clinically studied Bacopa preparations including CDRI-08 (KeenMind, Synapsa), BacoMind, and BaCognize. The aglycone cores of the constituent saponins are jujubogenin and pseudojujubogenin, linked to arabinose-glucose trisaccharide chains that modulate solubility, bioavailability, and receptor interaction profiles.

    The pharmacology of bacoside A is multi-target and operates through at least five characterized mechanisms: (1) enhancement of cholinergic neurotransmission through upregulation of choline acetyltransferase activity and inhibition of acetylcholinesterase; (2) modulation of serotonergic neurotransmission through interaction with 5-HT1A and 5-HT2C receptor subtypes, with downstream effects on anxiety, mood, and cognitive flexibility; (3) dopaminergic modulation in prefrontal and hippocampal circuits; (4) potent antioxidant neuroprotection through scavenging of reactive oxygen species, suppression of lipid peroxidation, and upregulation of endogenous antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase; and (5) inhibition of amyloid-beta peptide fibrillation and cytotoxicity through direct interaction with amyloid-beta (1-42), reducing aggregation and membrane disruption in neuronal cell models. Additional mechanisms include enhancement of brain-derived neurotrophic factor (BDNF) expression, promotion of hippocampal dendritic branching and synaptic density in the CA1 and CA3 regions, and modulation of GABAergic neurotransmission.

    The clinical evidence base for Bacopa monnieri standardized to bacoside A content comprises at least nine randomized, double-blind, placebo-controlled trials in healthy adults, elderly populations, and children, conducted principally at Swinburne University of Technology (Stough laboratory), the University of Wollongong (Roodenrys laboratory), and multiple Indian academic medical centers. The consistent finding across these trials is statistically significant improvement in speed of visual information processing, learning rate, memory consolidation, and delayed recall after 8 to 12 weeks of oral administration at 300 to 450 mg per day of extract standardized to 50 to 55 percent bacosides, with secondary anxiolytic effects and reduction in state anxiety scores. Effect onset requires sustained administration; acute single-dose cognitive enhancement has not been reliably demonstrated. A 2012 systematic review by Pase et al. confirmed the cognitive-enhancing effects across six qualifying trials and identified memory consolidation as the most reproducible endpoint.

    Pharmacokinetic characterization of isolated bacoside A in humans remains incomplete. In silico ADMET analyses of the constituent saponins and their aglycone derivatives indicate favorable predicted oral absorption for the aglycones (jujubogenin, pseudojujubogenin), with central nervous system drug-like properties including adequate predicted blood-brain barrier penetration. The intact glycosides are poorly water-soluble and are believed to undergo gastrointestinal hydrolysis to active aglycone metabolites, a transformation consistent with the delayed onset of clinical effect observed in human trials. Hepatic metabolism involves cytochrome P450 enzymes; Bacopa monnieri standardized extract has been demonstrated to inhibit CYP3A4, CYP2C9, CYP2C19, and CYP1A2 in vitro at estimated gut concentrations, with potential for clinically significant herb-drug interactions.

    The compound is well tolerated at standard doses (300 to 600 mg per day of standardized extract). The principal adverse events are mild gastrointestinal disturbances (nausea, abdominal cramps, increased stool frequency) that typically attenuate with continued use. No hepatotoxicity has been reported despite widespread use. A thyroid-stimulating effect (elevation of serum T4) has been characterized in animal studies and warrants caution in individuals with thyroid disorders. This monograph reviews the chemistry, biosynthesis, and structural characterization of bacoside A; the multi-target molecular pharmacology; the pharmacokinetic profile; the preclinical neuroprotective and cognitive evidence; the clinical trial evidence base; sourcing and quality verification for standardized extracts; reconstitution and handling; stack interactions; adverse events and safety; and a comparative assessment of five alternative nootropic candidates (Hericium erinaceus, Ginkgo biloba EGb 761, phosphatidylserine, alpha-GPC, and citicoline) against bacoside A on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1614Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • 25CN-NBOH

    Selective serotonin 5-HT2A receptor agonist of the N-benzyl phenethylamine (NBOH) structural class

    A high-affinity, brain-penetrant N-(2-hydroxybenzyl) phenethylamine developed at the University of Copenhagen as the most selective commercially available 5-HT2A receptor agonist tool compound, distinguished from classical serotonergic psychedelics by exceptional subtype selectivity and from the NBOMe series by a superior safety margin.

    Abstract

    25CN-NBOH (4-[2-[(2-hydroxyphenyl)methylamino]ethyl]-2,5-dimethoxybenzonitrile) is a synthetic phenethylamine of the N-benzyl-2-hydroxybenzyl (NBOH) structural class, first reported in 2014 by Hansen and colleagues at the University of Copenhagen as a potent and highly selective agonist of the serotonin 5-HT2A receptor. With a binding affinity (Ki) of approximately 0.81 to 1.32 nanomolar at the human 5-HT2A receptor and 52- to 100-fold selectivity over the closely related 5-HT2C receptor, 25CN-NBOH represents one of the most 5-HT2A-selective agonists described in the published literature and the most selective commercially available tool compound for interrogation of 5-HT2A receptor function in vitro and in vivo.

    The compound occupies a distinctive pharmacological niche. Unlike psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine, which activate multiple serotonin receptor subtypes and, in the case of LSD, dopamine and adrenergic receptors, 25CN-NBOH provides a pharmacological lever with which 5-HT2A-mediated effects can be isolated from confounding receptor contributions. Unlike the structurally related NBOMe series (25I-NBOMe, 25C-NBOMe, 25B-NBOMe), which carry an N-methoxybenzyl substituent and have been associated with serious toxicity and fatalities in recreational contexts, 25CN-NBOH carries an N-(2-hydroxybenzyl) group that confers a more favorable preclinical safety profile and improved metabolic stability.

    The pharmacological characterization of 25CN-NBOH has advanced substantially since 2014. A tritiated radioligand ([3H]25CN-NBOH) has been synthesized and validated for equilibrium and kinetic binding assays and for autoradiography in rat brain, providing high-resolution mapping of 5-HT2A receptor distribution. The cryo-electron microscopy structure of 25CN-NBOH bound to the human 5-HT2A receptor in complex with a mini-Gaq heterotrimer, solved at 3.27 angstrom resolution by Kim et al. (2020) and published in Cell, provided the first atomic-resolution view of a hallucinogen-activated serotonin receptor and has become a foundational reference for structure-based drug design in the serotonergic psychedelic field. Structure-activity relationship studies have mapped the 2-prime and 3-prime positions of the N-benzyl ring as critical determinants of 5-HT2A agonist activity and have identified conformationally restrained analogs and beta-arrestin-biased derivatives that enable pathway-selective pharmacology.

    Preclinical pharmacology in rodent models has characterized 25CN-NBOH across multiple behavioral and physiological endpoints. In mice, the compound produces a dose-dependent head-twitch response (the canonical 5-HT2A-mediated behavioral readout) with an inverted U-shaped dose-response curve peaking at 1.5 mg/kg and a half-maximal time of approximately 11 minutes, with both tachyphylaxis within sessions and tolerance across days consistent with 5-HT2A receptor desensitization. In rats, a single administration of 25CN-NBOH reduces immobility in the forced swim test with an effect size persisting without decrement for at least three months, paralleling the long-lasting antidepressant-like activity of psilocybin and supporting the hypothesis that 5-HT2A receptor activation underlies the enduring behavioral effects of serotonergic psychedelics. A single dose enhances cognitive flexibility in a reversal learning paradigm two to three weeks after administration. Additional preclinical findings include reduction of conditioned fear (blocked by the 5-HT2A inverse agonist MDL100907), reduction of marble burying behavior, cardiovascular effects including tachycardia and temperature-dependent modulation of carotid blood flow, and complex dual actions on medial prefrontal cortical neurons comprising 5-HT2A-dependent excitatory synaptic enhancement and 5-HT2A-independent M-current-mediated suppression of neuronal firing.

    Pharmacokinetic characterization in mice demonstrates rapid brain penetration (free brain and plasma concentrations of approximately 200 nanomolar within 15 minutes after 3 mg/kg subcutaneous administration), high in vitro permeability (apparent permeability coefficient 29 times 10 to the negative 6 centimeters per second), and low P-glycoprotein-mediated efflux. The compound is metabolized more slowly than the NBOMe congeners and displays favorable physicochemical properties including aqueous stability of the hydrochloride salt at room temperature for weeks.

    No human clinical trials of 25CN-NBOH have been conducted or registered as of the monograph date. The compound is not approved for any therapeutic indication in any jurisdiction and is classified as a controlled substance in the United Kingdom (Class A), Hungary, and Canada, and is potentially controlled in the United States under the Federal Analogue Act when intended for human consumption. This monograph reviews the chemistry, synthesis, receptor pharmacology, structural biology, pharmacokinetics, preclinical behavioral and physiological pharmacology, sourcing and handling considerations, and comparative assessment of 25CN-NBOH against five alternative 5-HT2A receptor agonists on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1591Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Schisandrin B

    Dibenzocyclooctadiene lignan with pleiotropic antioxidant, hepatoprotective, anti-inflammatory, and cytoprotective activity

    A principal bioactive dibenzocyclooctadiene lignan isolated from the fruit of Schisandra chinensis, distinguished by potent Nrf2-dependent antioxidant induction, NF-kB suppression, mitochondrial protective activity, and hepatoprotective efficacy across multiple preclinical models of chemical, ischemic, and metabolic liver injury.

    Abstract

    Schisandrin B (Sch B), also designated gamma-schisandrin, is the most pharmacologically characterized dibenzocyclooctadiene lignan isolated from the dried ripe fruit of Schisandra chinensis (Turcz.) Baill., a climbing vine of the family Schisandraceae with a history of use in traditional Chinese medicine spanning more than two millennia under the name wuweizi (five-flavor berry). Among the more than 30 structurally related lignans present in the Schisandra fruit, Schisandrin B has attracted the greatest research attention owing to a convergence of potent antioxidant, anti-inflammatory, hepatoprotective, cardioprotective, and neuroprotective activities demonstrated across a substantial body of in vitro and in vivo preclinical literature. The compound acts principally through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor and its downstream antioxidant response element (ARE)-dependent gene program, producing upregulation of glutathione S-transferase, heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, superoxide dismutase, and catalase. Concurrently, Schisandrin B suppresses NF-kB nuclear translocation and downstream proinflammatory cytokine expression (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) through inhibition of IkB-alpha degradation and suppression of MAPK cascade phosphorylation at c-Raf, MEK, ERK, JNK, and p38 nodes. Additional characterized mechanisms include enhancement of mitochondrial glutathione antioxidant status and heat shock protein induction, activation of the SIRT1/PI3K/Akt and AMPK/mTOR signaling axes, suppression of ferroptosis through upregulation of SLC7A11, GPX4, and FTH1, and modulation of pregnane X receptor (PXR)-mediated bile acid metabolism. The hepatoprotective activity is the best-validated pharmacological property: Schisandrin B protects against carbon tetrachloride-induced hepatotoxicity, D-galactosamine-induced hepatocyte apoptosis, ischemia-reperfusion liver injury, doxorubicin and pirarubicin-induced hepatotoxicity, acetaminophen hepatotoxicity, cholestatic liver injury, and metabolic-associated fatty liver disease in rodent models, with efficacy demonstrated at oral doses typically in the range of 25 to 100 mg/kg in mice and rats. The compound also exhibits preclinical cardioprotective activity against doxorubicin cardiotoxicity and angiotensin II-induced cardiac fibrosis, and neuroprotective activity against amyloid-beta-induced neuronal dysfunction, scopolamine-induced amnesia, and cisplatin-induced neurotoxicity. Pharmacokinetic characterization in rats demonstrates oral bioavailability of approximately 19 to 55 percent (with sex-dependent variation), extensive hepatic accumulation consistent with its liver-protective profile, a double-peak absorption curve suggestive of enterohepatic circulation, and linear pharmacokinetics across the 10 to 40 mg/kg oral dose range. Schisandrin B is a potent, dose-dependent, noncompetitive inhibitor of CYP3A activity (Ki approximately 16.6 mg/kg in vivo) and inhibits P-glycoprotein-mediated efflux, producing clinically relevant herb-drug interactions with CYP3A substrates including midazolam, tacrolimus, and sirolimus. The compound has not been evaluated in human clinical trials as an isolated entity; all pharmacological and safety characterization derives from preclinical studies and from clinical experience with Schisandra chinensis fruit extracts and the semi-synthetic derivative bifendate (dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate). Preclinical toxicology in dogs has demonstrated dose-dependent plasma accumulation on repeated administration, and in vitro studies at high concentrations have identified paradoxical hepatotoxicity in mouse hepatocytes and macrophages, indicating that the therapeutic window requires careful characterization before clinical translation. This monograph documents the chemistry, stereochemistry, and botanical source of Schisandrin B; the molecular pharmacology across Nrf2, NF-kB, SIRT1, AMPK, and mitochondrial mechanisms; the preclinical pharmacokinetic profile; the comprehensive preclinical evidence base across hepatoprotective, cardioprotective, neuroprotective, anti-inflammatory, and antitumor indications; sourcing and quality verification; reconstitution and handling; stack interactions with emphasis on CYP3A and P-glycoprotein; adverse events and safety signals including dose-dependent hepatotoxicity; and a comparative assessment of five related hepatoprotective or Nrf2-activating compounds against Schisandrin B on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1610Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Cytoflavin

    Fixed-dose combination metabolic cytoprotectant comprising succinic acid, inosine, nicotinamide, and riboflavin for mitochondrial energy rescue and antihypoxant neuroprotection

    A four-component metabolic combination drug developed by POLYSAN Ltd. that supplies Krebs cycle substrate, purine nucleoside, NAD+ precursor, and FAD cofactor to restore aerobic energy production in ischemic, hypoxic, and neurodegenerative tissue.

    Abstract

    Cytoflavin is a fixed-dose combination metabolic agent comprising succinic acid (the principal mass component and Krebs cycle substrate), inosine (a purine nucleoside and precursor to adenine nucleotides), nicotinamide (the amide form of vitamin B3 and precursor to nicotinamide adenine dinucleotide), and riboflavin (vitamin B2, the precursor to flavin adenine dinucleotide and flavin mononucleotide). Developed and manufactured by POLYSAN Scientific and Technological Pharmaceutical Company (Saint Petersburg, Russia), the product is formulated as enteric-coated tablets (300 mg succinic acid, 50 mg inosine, 25 mg nicotinamide, 5 mg riboflavin per tablet) and as a concentrate for intravenous infusion (1000 mg succinic acid, 200 mg inosine, 100 mg nicotinamide, 20 mg riboflavin sodium phosphate per 10 mL ampoule, with meglumine and sodium hydroxide as excipients). The pharmacological rationale is the simultaneous provision of four complementary metabolic substrates and cofactors whose intracellular availability becomes rate-limiting during ischemia, hypoxia, and oxidative stress: succinic acid feeds directly into mitochondrial Complex II (succinate dehydrogenase), bypassing the NAD-dependent steps of the Krebs cycle that fail under hypoxic conditions; inosine supports purine salvage and ATP resynthesis; nicotinamide replenishes the NAD+ pool consumed by poly(ADP-ribose) polymerase activation during ischemic injury; and riboflavin provides the FAD prosthetic group required for succinate dehydrogenase function and for multiple flavoprotein-dependent antioxidant enzymes including glutathione reductase.

    The clinical evidence base for Cytoflavin spans ischemic stroke (acute and chronic cerebral ischemia), traumatic brain injury, diabetic polyneuropathy, postoperative cognitive decline in elderly surgical patients, post-COVID-19 asthenic syndrome, and organic asthenic disorder. The largest and most rigorous published trial is the CYLINDER study, a multicenter, double-blind, placebo-controlled, randomized trial in 216 patients with type 2 diabetes mellitus and symptomatic distal sensorimotor diabetic polyneuropathy conducted across 10 Russian clinical centers, which reported a statistically significant reduction in Total Symptom Score (TSS change of negative 2.65 points in the experimental group versus negative 1.73 points in the placebo group, p less than 0.001) after a sequential intravenous-then-oral treatment regimen. In acute ischemic stroke, multicenter studies have demonstrated marked reduction in neurological deficit severity by day 10 and higher probability of favorable functional outcome compared to standard-of-care controls. The CITADEL prospective randomized study demonstrated a pronounced anti-asthenic effect and correction of cognitive impairments in post-COVID-19 rehabilitation. An international, multicenter, randomized, single-blind, placebo-controlled trial (NCT04631484) evaluating Cytoflavin in moderate traumatic brain injury in adults was completed in 2024, with results published in Frontiers in Neurology in 2025, representing the first large-scale international trial of the compound outside the Russian Federation and Commonwealth of Independent States.

    Cytoflavin is registered as a medicinal product in the Russian Federation and in Vietnam. The manufacturing facility holds GMP EU certification. The compound is not approved by the United States Food and Drug Administration, by the European Medicines Agency, or by other major Western regulatory authorities. The clinical literature is predominantly in Russian-language journals, with an expanding body of English-language publications in international peer-reviewed venues. The safety profile across published clinical studies is favorable; the principal adverse events are transient epigastric discomfort, headache, hyperuricemia (attributable to inosine-derived purine catabolism), and rare hypersensitivity reactions. No serious adverse events attributable to the drug have been reported in published controlled trials.

    This monograph reviews the composition, identification, and formulation chemistry of Cytoflavin; the individual and composite pharmacology of its four active components; the pharmacokinetic considerations for each component; the preclinical pharmacology; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative neuroprotective metabolic agents (Mexidol, Actovegin, Cerebrolysin, citicoline, and Reamberin) against Cytoflavin on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1583Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.